Literature DB >> 12773130

Influence of renal function on clinico-pathological features of primary hyperparathyroidism.

Hiroyuki Yamashita1, Shiro Noguchi, Shinya Uchino, Shin Watanabe, Tsukasa Murakami, Takahiro Ogawa, Toshihiro Masatsugu, Yuji Takamatsu, Eiji Miyatake, Hiroto Yamashita.   

Abstract

OBJECTIVE: Disturbed renal function may play an important role in the clinico-pathological presentation of primary hyperparathyroidism (pHPT). We studied the influence of renal function on the clinico-pathological characteristics of 141 patients (123 women and 18 men) with surgically proven pHPT.
METHODS: The 141 patients were assigned to one of two groups based on creatinine clearance (C(cr)) level: a renal insufficiency group (n=37) in which C(cr) of patients was <70 ml/min and a normal renal function group (n=104) in which C(cr) was > or =70 ml/min. Clinical presentation and biochemical indices were evaluated and compared between the two groups.
RESULTS: Age, and frequency of hypertension and of diabetes mellitus were significantly (P<0.001, P<0.05 and P<0.05 respectively) higher in the renal insufficiency group than in the normal renal function group. Serum levels of calcium, intact parathyroid hormone and bone Gla protein were significantly (P<0.05) higher and the excised parathyroid weighed significantly more (P<0.05) in the renal insufficiency group than in the normal renal function group; however, serum 1,25-dihydroxyvitamin D (1,25(OH)(2)D) and 24 h urinary calcium excretion were significantly (P<0.001 and P<0.05 respectively) lower in the former than in the latter group. There was a significant inverse correlation between C(cr) level and serum calcium (r=0.315, P<0.001) and a significant positive correlation between C(cr) level, 1,25(OH)(2)D (r=0.315, P<0.001), and 24 h calcium excretion (r=0.458, P<0.0001).
CONCLUSIONS: Clinico-pathological features of pHPT were notably influenced by even moderate renal insufficiency. Urinary calcium excretion decreased according to the decrease in glomerular filtration rate. Therefore, endocrinologists need to appraise urinary calcium excretion and renal function of pHPT patients when considering surgery or in discriminating familial hypocalciuric hypercalcemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773130     DOI: 10.1530/eje.0.1480597

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Effect of renal function on skeletal health in primary hyperparathyroidism.

Authors:  Marcella D Walker; David W Dempster; Donald J McMahon; Julia Udesky; Elizabeth Shane; John P Bilezikian; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

2.  Predictors of renal function in primary hyperparathyroidism.

Authors:  Marcella D Walker; Thomas Nickolas; Anna Kepley; James A Lee; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2014-02-14       Impact factor: 5.958

3.  Surgery or no surgery: What works best for the kidneys in primary hyperparathyroidism? A study in a multi-ethnic Asian population.

Authors:  Yu Kwang Donovan Tay; Joan Khoo; Manju Chandran
Journal:  Indian J Endocrinol Metab       Date:  2016 Jan-Feb

Review 4.  Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.

Authors:  A A Khan; D A Hanley; R Rizzoli; J Bollerslev; J E M Young; L Rejnmark; R Thakker; P D'Amour; T Paul; S Van Uum; M Zakaria Shrayyef; D Goltzman; S Kaiser; N E Cusano; R Bouillon; L Mosekilde; A W Kung; S D Rao; S K Bhadada; B L Clarke; J Liu; Q Duh; E Michael Lewiecki; F Bandeira; R Eastell; C Marcocci; S J Silverberg; R Udelsman; K Shawn Davison; J T Potts; M L Brandi; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-09-09       Impact factor: 4.507

5.  Total and free vitamin D metabolites in patients with primary hyperparathyroidism.

Authors:  L Meng; C Su; S A Shapses; X Wang
Journal:  J Endocrinol Invest       Date:  2021-07-19       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.